Double-T Phase 2 Trial of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma
Summary
NIH registered Phase 2 clinical trial NCT07542678 (Double-T) on ClinicalTrials.gov, investigating a glofitamab-based double T-cell therapy strategy in high-risk relapsed/refractory large B-cell lymphoma patients eligible for CAR-T cell therapy. The trial will collect safety, efficacy, and quality of life data across induction and consolidation phases.
What changed
NIH published a clinical trial registration for the Double-T study, a prospective, randomized, open-label, multicenter Phase II trial. The trial evaluates a double T-cell therapy strategy combining glofitamab with gemcitabine/oxaliplatin as induction therapy followed by glofitamab monotherapy consolidation after standard CAR-T cell therapy in high-risk second-line relapsed/refractory large B-cell lymphoma patients. Conditions, interventions, and study milestones are listed.
Healthcare providers and clinical investigators participating in CAR-T or lymphoma research programs should note this trial's inclusion criteria and intervention arms. The trial is registered with NIH as the sponsor, and study data will be collected prospectively across multiple centers.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept
Phase 2 NCT07542678 Kind: PHASE2 Apr 21, 2026
Abstract
The Double-T trial is a prospective, randomized, single-arm, open-label, multicenter phase II trial investigating a double T-cell therapy strategy, which includes glofitamab with gemcitabine/oxaliplatin (Glofi-Gem/Ox) prior to and glofitamab monotherapy consolidation after standard of care Chimeric Antigen Receptor (CAR)-T cell therapy in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma (r/r LBCL) patients.
Data on safety, efficacy, and quality of life (QoL) will be collected and analyzed.
Conditions: Relapsed /Refractory DLBCL
Interventions: Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy, Glofitamab as Consolidation therapy
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.